Freenome

Paid

Empowering early cancer detection through a multiomics AI platform and routine blood tests.

Capabilities: Early Cancer Screening Biomarker Discovery Molecular Profiling Patient Risk Stratification

9.5

Protocol Reliability Score

Overview

Freenome is a pioneering biotechnology company utilizing a multiomics platform integrated with advanced machine learning to detect cancer at its earliest, most treatable stages. By analyzing a combination of tumor-derived signals and the body's holistic immune response from a standard blood draw, Freenome's AI architecture identifies high-dimensional patterns across genomic, proteomic, and epigenetic data layers. As of 2026, Freenome has solidified its market position by expanding from its cornerstone Colorectal Cancer (CRC) screening tool into a comprehensive Multi-Cancer Early Detection (MCED) suite. The technical backbone employs deep learning ensembles trained on massive clinical cohorts, allowing for the differentiation of malignant signals from background biological noise with industry-leading sensitivity and specificity. The platform is designed for seamless clinical integration, providing physicians with actionable insights that bridge the gap between complex molecular biology and routine patient care, effectively shifting the oncology paradigm from reactive treatment to proactive prevention.